Introduction/Overview
Diabetes, especially type 2 diabetes, has become a chronic metabolic disease that seriously threatens human health worldwide. its core pathophysiological characteristics include insulin resistance and progressive failure of pancreatic beta cell function. Although existing hypoglycemic drugs such as metformin, sulfonylureas, DPP-4 inhibitors, SGLT2 inhibitors, etc. have been widely used in clinical practice, the side effects, decreased efficacy, and the need for multi-target regulation caused by long-term use have prompted researchers to continuously search for candidate molecules with novel structures, unique mechanisms of action, and higher safety from natural products. Natural products have always been an important source of innovative drug discovery due to their structural diversity and rich biological activity.
4-Methoxy-2-[(6-O-β-D-xylopyranosyl-β-D-glucopyranosyl)oxy]benzaldehyde（CAS: 140484-68-0） It is a naturally occurring aromatic aldehyde glycoside with a unique structure. Its molecular structure integrates benzaldehyde core, methoxy substitution, and a disaccharide chain composed of xylose and glucose. This glycosylation modification not only significantly affects its physicochemical properties (such as water solubility), but is also closely related to specific biological activities and target recognition abilities. Preliminary pharmacological studies suggest that this compound has the potential of multi target action in anti diabetes, involving multiple key links such as energy metabolism regulation, insulin signal pathway enhancement, glucose transport, etc. The purpose of this paper is to systematically review the chemical characteristics, plant origin, pharmacological activity, mechanism of action, pharmaceutical properties and the development prospect of this compound as a candidate drug for anti diabetes, in order to provide reference for further research in related fields.
Chemical structure and physicochemical properties
The systematic naming of the compound clearly describes its structural features: 4-Methoxy-2- [(6-O - β - D-xylopyranosyl - β - D-glucuronosyl) oxy] benzaldehyde. Its molecular formula is C19H26O13 and its molecular weight is 446.4050 g/mol.
Structurally, its parent nucleus is benzaldehyde, which is connected to a disaccharide chain through an oxygen atom at position 2 (ortho) of the benzene ring, and substituted with a methoxy group at position 4 (para). The disaccharide chain is composed of one molecule of β - D-glucopyranose and one molecule of β - D-xylose connected by glycosidic bonds. The specific connection method is that the xylose group is connected to the oxygen atom at the 6th position of the glucose group, forming a 6-O - β - D-xylose - β - D-glucose group, which is a fragment of the so-called "xyloglucan" or "xyloglucan" type. This glycosylation structure classifies it as an aromatic aldehyde glycoside compound.
The theoretical physicochemical parameters calculated based on its structure show that its lipid water partition coefficient (LogP) is -1.1124, indicating that the compound has a high degree of hydrophilicity. The topologically polar surface area (TPSA) is as high as 184.60 Å ², mainly attributed to the numerous oxygen atoms in the molecule (from aldehyde, methoxy, multiple hydroxyl, and glycosidic oxygen), further confirming its strong polarity characteristics. The calculated water solubility value is 35.1378mg/L, which belongs to the solubility range. Good water solubility is beneficial for its distribution and absorption in aqueous media such as biological fluids. These properties are mainly determined by its glycosidic portion, and the presence of sugar chains greatly improves the solubility of benzaldehyde parent nuclei.
Preliminary pharmacological risk assessment shows that the compound has a low ability to cross the blood-brain barrier, which reduces its potential risk of central nervous system side effects. In the hERG channel inhibition test, it showed a negative result, indicating a lower risk of inducing QT interval prolongation in the heart. The Ames test result is 0.6 (usually expressed as mutation rate, subject to specific experimental criteria, which usually implies a low risk of mutagenicity), indicating that its genetic toxicity risk may be controllable. These preliminary data provide a favorable starting point for its further development.
Plant sources and extraction methods
At present, there are relatively limited public literature reports on 4-Methoxy-2- [(6-O - β - D-xylopyranosyl - β - D-glucopyranosyl) oxy] benzaldehyde, and its specific plant source information is not fully clear in public databases. However, based on its structural type (aromatic aldehyde glycosides) and known knowledge of plant chemistry, it can be inferred that it may originate from certain specific families and genera of plants.
There are many plant species that contain compounds similar to benzaldehyde glycosides or phenylpropanoid glycosides, commonly found in Scrophulariaceae, Orobanchaceae, Plantaginaceae, Asteraceae And some The bark or heartwood of medicinal trees In the middle. For example, in the traditional medicinal plants used for anti-inflammatory, antioxidant or diabetes management, benzene ring derivatives with glycoside modification can often be isolated. Future research requires systematic phytochemical screening to selectively isolate and identify the compound from plant extracts of these families and genera.
In terms of extraction methods, for natural products with high polarity and glycosidic bonds, the conventional extraction and separation process is usually as follows:
1. Extract Extract using medium to polar solvents such as methanol, ethanol, or ethanol water mixed solvents (such as 70% ethanol). These solvents can effectively dissolve glycoside components. Extraction techniques can include cold soaking, hot reflux, or more efficient ultrasound assisted extraction, microwave-assisted extraction, etc.
2. Preliminary enrichment After the extraction solution is concentrated under reduced pressure, the obtained extract can be subjected to gradient extraction using solvents such as petroleum ether, ethyl acetate, n-butanol, etc. Due to its strong hydrophilicity, the compound may mainly accumulate in the n-butanol extraction site or water layer.
3. Separation and purification Further chromatographic separation of parts rich in target components. Large pore adsorption resin column chromatography (such as D101, AB-8) is commonly used for sugar removal and preliminary segmentation. Subsequently, silica gel column chromatography, reverse phase silica gel column chromatography (such as ODS, C18), dextran gel column chromatography (such as Sephadex LH-20), etc. were used for repeated separation. High performance liquid chromatography (HPLC), especially preparative or semi preparative reverse phase HPLC, is the key final step in obtaining high-purity monomers. Its UV absorption characteristics (benzaldehyde and benzene ring conjugated structure) can be used for detection.
4. Structural Identification By using nuclear magnetic resonance spectroscopy (1H NMR, 13C NMR, 2D NMR such as HSQC, HMBC), mass spectrometry (ESI-MS, HR-ESI-MS), infrared spectroscopy (IR), and optical rotation measurement, and comparing with known data or synthetic controls, the planar structure and stereoconfiguration of the compound are finally determined.
Pharmacological activity research
The existing research clues (based on the provided target information) strongly suggest that the core pharmacological activity of 4-Methoxy-2- [(6-O - β - D-xylopyranosyl - β - D-glucopyranosyl) oxy] benzaldehyde is focused on anti-diabetic The field exhibits characteristics of multi-target and multi pathway effects. Its potential pharmacological effects may be reflected in the following aspects:
-
Improving insulin resistance and enhancing insulin sensitivity This compound may improve the sensitivity of peripheral tissues (such as fat, muscle, and liver) to insulin by acting on peroxisome proliferator activated receptor gamma (PPARG) and insulin receptor substrate 1 (IRS1). Activation of PPARG is the mechanism of action of thiazolidinedione drugs (such as Rosiglitazone), which can promote adipocyte differentiation, increase lipid storage, and improve systemic insulin sensitivity. Meanwhile, enhancing tyrosine phosphorylation of IRS1 is a key initiating step in insulin signaling.
-
Activate the energy metabolism regulatory pathway Adenosine activated protein kinase (AMPK) is a core sensor and regulator of cellular energy metabolism. This compound may directly or indirectly activate AMPK (encoded by subunits such as PRKAA1). The activation of AMPK can promote glucose uptake (by upregulating GLUT4), inhibit liver gluconeogenesis, promote fatty acid oxidation, thereby comprehensively reducing blood glucose and blood lipids, simulating the partial beneficial effects of exercise or metformin.
-
Promote glucose uptake and utilization This compound may promote the translocation of glucose transporter 4 (SLC2A4/GLUT4) to the cell membrane and increase glucose uptake by muscle and adipocytes by activating the phosphatidylinositol 3-kinase (PI3K, whose regulatory subunit is PIK3R1) - protein kinase B (AKT1) signaling pathway. Meanwhile, it may have a regulatory effect on glucokinase (GCK), which is the rate limiting enzyme for glucose metabolism in liver and pancreatic beta cells. Its activation can promote liver glucose utilization and insulin secretion.
-
Regulating renal glucose reabsorption and enteropancreatin metabolism This compound may have inhibitory effects on sodium glucose cotransporter 2 (SGLT2) and dipeptidyl peptidase-4 (DPP4). Inhibiting SGLT2 can reduce the reabsorption of glucose by the proximal tubules of the kidney, increase urinary glucose excretion, and directly lower blood glucose. This is the mechanism of action of novel SGLT2 inhibitors such as empagliflozin. Inhibiting DPP4 can prolong the activity of endogenous glucagon like peptide-1 (GLP-1), promote glucose dependent insulin secretion, and inhibit glucagon release.
To sum up, the compound may show comprehensive anti diabetes effects in cell and animal models:Reduce fasting and postprandial blood glucose, improve glucose tolerance, alleviate insulin resistance, regulate lipid metabolism, and potentially protect pancreatic beta cell function However, it should be emphasized that these activity speculations are mainly based on their associated target information, and specific in vitro and in vivo pharmacological experimental data need further research reports to confirm and quantify.
Mechanism of action and molecular targets
The molecular mechanism of this compound's anti diabetes activity may involve a complex network, which cooperatively regulates glucose homeostasis through interaction with multiple key targets. The following is a detailed explanation of its potential mechanism of action and molecular targets:
-
Activation of AMPK signaling pathway AMPK is the main switch for metabolic regulation. This compound may act as a direct allosteric activator of AMPK, or indirectly activate AMPK by consuming cellular ATP (such as acting as a mild uncoupling agent for the mitochondrial respiratory chain), increasing the AMP/ATP ratio, and so on. Activated AMPK produces multiple effects by phosphorylating downstream targets: a) phosphorylating and inhibiting acetyl CoA carboxylase (ACC), promoting fatty acid oxidation, reducing lipid accumulation, and improving insulin resistance; b) Upregulation of GLUT4 expression and promotion of its membrane translocation increase glucose uptake in skeletal muscle and adipocytes; c) Inhibit the activity of key transcription factors and enzymes involved in gluconeogenesis in the liver, such as CREB and PGC-1 α, and reduce endogenous glucose production.
-
Enhancement of insulin signaling pathway：
- IRS1/PI3K/AKT axis This compound may enhance insulin signaling by inhibiting serine phosphorylation of IRS1 (a negative feedback inhibition) or promoting its tyrosine phosphorylation. Activated IRS1 recruits and activates PI3K (composed of catalytic subunit and regulatory subunit PIK3R1), which then catalyzes the generation of PIP3. PIP3 recruits PDK1 and AKT1 (PKB) to the cell membrane, fully activating AKT1. Activated AKT1 is a key executor of downstream effects: promoting GLUT4 vesicle transport to the cell membrane; Inhibit glycogen synthase kinase-3 (GSK3 β) and promote glycogen synthesis; Inhibit FoxO1 transcription factor and downregulate gluconeogenesis gene expression.
- Regulation of PPARG As a nuclear receptor, activation of PPARG can induce the expression of a series of genes related to fat metabolism and insulin sensitization. This compound may act as a partial agonist or modulator of PPARG, while avoiding side effects such as edema and weight gain caused by traditional thiazolidinedione drugs (potent PPARG agonists), and improving insulin sensitivity.
-
Regulation of key enzymes in glucose metabolism The potential activation of glucokinase (GCK) can lower the "glucose sensing threshold" of liver and pancreatic beta cells. In the liver, enhanced GCK activity accelerates glucose phosphorylation to 6-phosphate glucose, promoting glycogen synthesis and glycolysis; In pancreatic beta cells, they can respond more sensitively to elevated blood sugar and promote insulin secretion.
-
Inhibition of SGLT2 and DPP4 This compound may directly competitively bind to the glucose binding site of renal SGLT2, inhibiting its transport function and leading to increased urinary glucose excretion. At the same time, it may inhibit the activity of DPP4 enzyme, slow down the degradation of GLP-1 and GIP, thereby enhancing the "enteropancreatin effect", promoting insulin secretion and inhibiting glucagon release when blood glucose levels rise.
Multi target synergistic effect The uniqueness of this compound lies in its potential simultaneous action on multiple targets mentioned above. For example, the activation of AMPK and AKT can synergistically promote GLUT4 translocation; Improving insulin sensitivity (through PPARG, IRS1) and promoting urinary glucose excretion (through SGLT2 inhibition) can lower blood glucose levels through different pathways; The incretin effect caused by DPP4 inhibition can also supplement insulin secretion. This multi target mode of action may bring more stable blood glucose control, lower risk of hypoglycemia and potential benefits for diabetes complications, but it also puts forward higher research requirements for its target selectivity, off target effect and safety.
Evaluation of drug properties and pharmacokinetics
Based on calculations and preliminary experimental data, a preliminary evaluation of the pharmacological properties of the compound is conducted
Advantage aspects：
1. Good water solubility and physicochemical properties High hydrophilicity (LogP-1.11, TPSA 184.6) and acceptable water solubility are beneficial for the development of formulations (such as oral solutions, injections) and may improve their in vivo distribution.
2. Preliminary safety signal positive No hERG inhibition signal, low risk of cardiac toxicity; The Ames test results indicate a low risk of genetic toxicity; Low blood-brain barrier permeability reduces concerns about central side effects.
3. Multi target potential As mentioned earlier, its multi-target effect may translate into better therapeutic efficacy and lower drug resistance.
Challenges and Key Issues to be Studied：
1. Oral bioavailability This is a common challenge faced by glycoside compounds. High molecular weight (446.4), high polarity, and glycosidic bonds may seriously affect its oral absorption. In the gastrointestinal tract, it may be destroyed by stomach acid, hydrolyzed by gut microbiota or glycosidase on the intestinal mucosa, releasing aglycones (4-methoxy-2-hydroxybenzaldehyde) and glycosides. The physicochemical properties (LogP may be higher) and activity of aglycones may differ from those of the original glycoside, and their pharmacokinetic and pharmacological contributions need to be clarified. The ability of the prototype compound to passively diffuse through intestinal epithelial cells is weak, and whether there is an active transport mechanism remains to be studied. Therefore, its oral bioavailability may be low.
2. Metabolic stability In addition to hydrolysis in the gastrointestinal tract, this compound may undergo extensive phase I metabolism (such as aldehyde oxidation) and phase II metabolism (such as glucuronic acid binding and sulfation) in the liver. Glycosides may also be metabolized by glycosidases in the liver or other tissues. It is necessary to conduct a detailed study on its metabolic profile and activity in vivo.
3. Pharmacokinetic characteristics The pharmacokinetic parameters of the drug need to be systematically studied through animal experiments (rats, dogs, etc.), including peak time after oral administration (Tmax), peak concentration (Cmax), half-life (t1/2), area under the drug time curve (AUC), and absolute bioavailability. Intravenous administration can evaluate its distribution volume, clearance rate, etc. The tissue distribution, especially the concentration in target organs (liver, muscle, fat, kidney), is crucial.
4. Protein binding rate It is necessary to determine its binding rate with plasma proteins (mainly albumin), which will affect its free drug concentration, distribution, and clearance.
5. Formulation strategy To improve oral bioavailability, advanced formulation techniques may be required, such as making prodrugs (protecting aldehyde or glycosidic bonds), using absorption enhancers, developing nano formulations (liposomes, nanoparticles), or using non oral administration routes (such as subcutaneous injection if systemic exposure is necessary).
Clinical application prospects and prospects
4-Method-2- [(6-O - β - D-xylopyranosyl - β - D-glucopyranosyl) oxygen] benzaldehide, as a natural product with multi-target anti diabetes potential, its future development prospects are full of opportunities as well as a series of scientific challenges that need to be overcome.
Potential application directions：
1. New multi target anti diabetes drug candidates If its multi target activity is confirmed in vivo and its safety is good, it may be developed as a new option for single drug treatment of mild to moderate type 2 diabetes, especially for patients with insulin resistance. Its mechanism of action covers some targets of multiple mainstream drug categories (insulin sensitizers, SGLT2 inhibitors, DPP4 inhibitors), which may produce synergistic effects.
2. Components of combination therapy Given its unique mechanism of action, this compound or its structurally optimized derivatives may be used in combination with existing hypoglycemic drugs with different mechanisms of action, such as metformin, to achieve more comprehensive and effective blood glucose control, and may reduce the dosage and side effects of each individual drug.
3. Prevention of complications of diabetes The activation of AMPK and regulation of the AKT pathway are not only related to glucose metabolism, but also to anti-inflammatory, antioxidant, endothelial function improvement, nerve and kidney protection effects. Therefore, this compound has the potential to delay or prevent the occurrence and development of cardiovascular complications, kidney disease and neuropathy in diabetes in long-term application, which needs special preclinical and clinical studies to verify.
4. Structural optimization of lead compounds Its chemical structure provides an optimized starting point for medicinal chemists. Structural modifications can be made to address its pharmacokinetic shortcomings, such as poor oral absorption and fast metabolism, such as modifying aldehyde groups to reduce chemical activity and metabolism; Modifying sugar groups to improve metabolic stability or introducing specific targeting groups; Simplify or replace sugar groups to balance lipophilicity and hydrophilicity, and improve membrane permeability.
Future research prospects and challenges：
1. Deepening basic research: The primary task is to complete systematic pharmacodynamic evaluation in vitro and in vivo, and confirm its specific efficacy and dose effect relationship in reducing blood sugar, improving insulin resistance, and regulating blood lipids in cell models (hepatocytes, muscle cells, adipocytes, β cells) and type 2 diabetes animal models (such as db/db mice, ZDF rats, high-fat diet combined with STZ induction model).
2. Confirmation of mechanism of action It is necessary to use various methods such as molecular docking, surface plasmon resonance (SPR), enzyme activity inhibition experiments, gene knockout/knockdown techniques, reporter gene systems, etc. to directly verify its interaction mode (excitation, inhibition, allosteric regulation) and affinity with targets such as AMPK, SGLT2, DPP4, PPARG, etc.
3. Comprehensive pharmacokinetic and toxicological studies After completing the preliminary efficacy verification, a systematic ADMET (absorption, distribution, metabolism, excretion, toxicity) study must be conducted. This includes detailed in vitro metabolic stability (liver microsomes, liver cells), transmembrane transport, CYP enzyme inhibition/induction potential assessment, as well as standardized preclinical safety evaluations for acute toxicity, subchronic toxicity, reproductive toxicity, etc.
4. Clinical development pathway If the preclinical research results are positive, we will follow the requirements of the New Drug Clinical Research (IND) application to prepare active pharmaceutical ingredients and formulations that meet GMP standards, and conduct Phase I (safety, tolerability, pharmacokinetics), Phase II (efficacy exploration, dose determination), and Phase III (large-scale efficacy, safety verification) clinical trials in humans. The entire process is time-consuming, requires significant investment, and carries high risks.
5. Natural product sources and sustainable supply It is necessary to clarify its natural source and conduct plant identification, evaluate the feasibility of large-scale extraction, or develop fully synthetic/semi synthetic routes to ensure a stable, economical, and sustainable supply of raw materials for future drug development.
Conclusion
4-Methoxy-2-[(6-O-β-D-xylopyranosyl-β-D-glucopyranosyl)oxy]benzaldehyde It is a natural aromatic aldehyde glycoside with novel structure and multi target anti diabetes potential. Its unique chemical structure endows it with good water solubility and preliminary favorable drug safety parameters. The pharmacological mechanism of action is speculated to involve multiple key targets closely related to glucose homeostasis regulation, such as AMPK activation, insulin signaling pathway enhancement, SGLT2 and DPP4 inhibition, demonstrating broad prospects for comprehensive regulation of glucose and lipid metabolism.
However, there is still a long scientific road to explore from natural products to candidate drugs. The current understanding of its activity is mostly based on target association speculation, lacking systematic experimental data support. The prominent challenges it faces, especially the oral bioavailability and metabolic stability issues as glycoside molecules, are the focus of future research. Through in-depth pharmacodynamic verification, accurate molecular mechanism clarification, reasonable pharmacokinetic optimization and comprehensive safety assessment, this compound is expected to become an excellent lead compound for developing a new generation of multi target anti diabetes drugs, or provide a new perspective for understanding the role of natural products in the treatment of metabolic diseases. The combination of continuous excavation of the treasure house of natural products and modern research means will continue to contribute valuable inspiration and resources to mankind's fight against complex diseases such as diabetes.
![4-Methoxy-2-[(6-O-β-D-xylopyranosyl-β-D-glucopyranosyl)oxy]benzaldehyde](/upload/0201/04/140484-68-0.gif)
